A Phase 2b Randomized, Double-masked, Active-controlled, Dose-response Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension

The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.

开始日期2023-08-28

申办/合作机构

D. Western Therapeutics Institute, Inc.

100 项与 D. Western Therapeutics Institute, Inc. 相关的临床结果

登录后查看更多信息

0 项与 D. Western Therapeutics Institute, Inc. 相关的专利（医药）

登录后查看更多信息

项与 D. Western Therapeutics Institute, Inc. 相关的文献（医药）

Cells3区 · 生物学

The Isoquinoline-Sulfonamide Compound H-1337 Attenuates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Rats

3区 · 生物学

ArticleOA

作者: Sanada, Takayuki Jujo ; Sakao, Seiichiro ; Sumi, Kengo ; Shoji, Hiroki ; Maruyama, Kazuo ; Maruyama, Junko ; Zhang, Erquan ; Yoshida, Yoko ; Naito, Akira ; Hidaka, Hiroyoshi ; Tatsumi, Koichiro

Pulmonary arterial hypertension (PAH) is characterized by elevated pulmonary arterial pressure and right heart failure. Selective pulmonary vasodilators have improved the prognosis of PAH; however, they are not able to reverse pulmonary vascular remodeling. Therefore, a search for new treatment agents is required. H-1337 is an isoquinoline-sulfonamide compound that inhibits multiple serine/threonine kinases, including Rho-associated protein kinase (ROCK) and mammalian target of rapamycin (mTOR). Here, we investigated the effects of H-1337 on pulmonary hypertension and remodeling in the pulmonary vasculature and right ventricle in experimental PAH induced by SU5416 and hypoxia exposure. H-1337 and H-1337M1 exerted inhibitory effects on ROCK and Akt. H-1337 inhibited the phosphorylation of myosin light chain and mTOR and suppressed the proliferation of smooth muscle cells in vitro. H-1337 treatment also suppressed the phosphorylation of myosin light chain and mTOR in the pulmonary vasculature and decreased right ventricular systolic pressure and the extent of occlusive pulmonary vascular lesions. Furthermore, H-1337 suppressed aggravation of right ventricle hypertrophy. In conclusion, our data demonstrated that inhibition of ROCK and mTOR pathways with H-1337 suppressed the progression of pulmonary vascular remodeling, pulmonary hypertension, and right ventricular remodeling.

PloS one3区 · 综合性期刊

Five-year follow-up of fundus autofluorescence and retinal sensitivity in the fellow eye in exudative age-related macular degeneration in Japan

3区 · 综合性期刊

ArticleOA

作者: Asato, Hitomi ; Ogura, Yuichiro ; Nakamura, Mayumi ; Iida, Tomohiro ; Hirano, Yoshio ; Kuno, Noriyuki ; Sugano, Yukinori ; Mori, Ryusaburo ; Oshima, Yuji ; Nishiyama, Takeshi ; Yuzawa, Mitsuko ; Kimura, Erika ; Matsuno, Kiyoshi ; Shinojima, Ari ; Sekiryu, Tetsuju ; Gomi, Fumi ; Yasukawa, Tsutomu ; Kato, Aki ; Hara, Chikako ; Sawa, Miki ; Ishibashi, Tatsuro ; Saito, Masaaki ; Ashikari, Masayuki

PURPOSE:

To assess the 5-year change in abnormal fundus autofluorescence (FAF) patterns and retinal sensitivity in the fellow eye of Japanese patients with unilateral exudative age-related macular degeneration (AMD).

METHODS:

Patients with unilateral exudative AMD who developed abnormal FAF in the fellow eyes were enrolled. FAF imaging and microperimetry were performed at baseline and follow-ups. FAF findings were classified into 8 patterns based on the International Fundus Autofluorescence Classification Group to assess retinal sensitivity. Forty-five points covering the central 12 degrees on microperimetry were superimposed onto the FAF images. Each point was classified depending on the distance from the abnormal FAF. "Close" was defined as the portion within 1 degree from the border of any abnormal FAF, and "Distant" was defined as the portion over 1 degree from the border of abnormal FAF. To investigate the association between the retinal sensitivity and distance from the abnormal FAF, hierarchical linear mixed-effect models were used with the distance, time and time squared from baseline (months), and angle (degrees) as fixed effects. Differences among patients, eyes, and test point locations were considered successively nested random effects.

RESULTS:

We studied 66 fellow eyes with abnormal FAF. Twenty-seven eyes were followed-up during the 5 years. In the 13 of 27 eyes (48%), the abnormal FAF patterns had changed during the 5 years. We found retinal sensitivity was associated significantly with the distance from the abnormal FAF ("Distant": p<0.001, time2 from baseline: p<0.001, angle: p<0.001). The mean retinal sensitivity of the "Close" tended to deteriorate after the third year and eventually showed the similar sensitivity as the portion within the abnormal FAF.

CONCLUSION:

FAF patterns can change about half during the 5 years and the retinal sensitivity near abnormal FAF tends to deteriorate after the third year.

PloS one3区 · 综合性期刊

Fundus autofluorescence and retinal sensitivity in fellow eyes of age-related macular degeneration in Japan

3区 · 综合性期刊

ArticleOA

作者: Iida, Tomohiro ; Ogura, Yuichiro ; Nakamura, Mayumi ; Ashikari, Masayuki ; Yasukawa, Tsutomu ; Hirano, Yoshio ; Mori, Ryusaburo ; Kuno, Noriyuki ; Ishibashi, Tatsuro ; Sugano, Yukinori ; Oshima, Yuji ; Nishiyama, Takeshi ; Yuzawa, Mitsuko ; Asato, Hitomi ; Kimura, Erika ; Gomi, Fumi ; Matsuno, Kiyoshi ; Kato, Aki ; Sawa, Miki ; Saito, Masaaki ; Sekiryu, Tetsuju ; Hara, Chikako ; Shinojima, Ari

PURPOSE:

Abnormal fundus autofluorescence (FAF) potentially precedes onset of late age-related macular degeneration (AMD) in Caucasian patients. Many differences exist between Asian and Caucasian patients regarding AMD types and severity, gender, and genetic backgrounds. We investigated the characteristics of abnormal FAF and retinal sensitivity in the fellow eyes of Japanese patients with unilateral neovascular AMD.

METHODS:

Sixty-six patients with unilateral neovascular AMD and abnormal FAF in the fellow eye were enrolled in this multicenter, prospective, observational study. The best-corrected visual acuity, fundus photographs, FAF images, and retinal sensitivity on microperimetry were measured periodically for 12 months. The FAF images were classified into eight patterns based on the International Fundus Autofluorescence Classification Group. The points measured by microperimetry were superimposed onto the FAF images and fundus photographs and classified as "within," "close," and "distant," based on the distance from the abnormal FAF and other findings. The relationship between the location of the baseline abnormal FAF and retinal sensitivity was investigated.

RESULTS:

In Japanese patients, patchy (33.3%) and focally increased (30.3%) patterns predominated in the abnormal FAF. Intermediate-to-large drusen was associated predominantly with hyperfluorescence and hypofluorescence. Neovascular AMD developed within 1 year in six (9.1%) eyes, the mean baseline retinal sensitivity of which was 12.8 ± 4.7 dB, significantly (p<0.002) lower than the other eyes. In 44 of the other 60 eyes, microperimetry was measurable at baseline and month 12 and the mean retinal sensitivity improved significantly from 13.5 ± 4.4 to 13.9 ± 4.8 dB (p<0.001), possibly associated with lifestyle changes (e.g., smoking cessation, antioxidant and zinc supplementation). The mean retinal sensitivities of points within and close to the abnormal FAF were 9.9 and 11.7 dB, respectively, which were significantly lower than the 14.0 dB of the points distant from the abnormal FAF.

CONCLUSION:

In Japanese patients, patchy and focally increased patterns predominated in the abnormal FAF. The retinal sensitivity was lower close to/within the abnormal FAF. FAF and microperimetry are useful to assess macular function before development of neovascular AMD or geographic atrophy.

项与 D. Western Therapeutics Institute, Inc. 相关的新闻（医药）

2022-09-27

·PRNewswire

Open-Angle Glaucoma Therapeutics Market to Record a CAGR of 7.18%, Development of Biologics to be a Key Trend - Technavio

NEW YORK, Sept. 27, 2022 /PRNewswire/ -- One of the key trends in the open-angle glaucoma therapeutics market is the development of biologics. The market landscape largely contains small molecules, including PGAs and non-PGAs. These molecules are the main option for the treatment of open-angle glaucoma. However, side effects such as lack of patient adherence and the high cost of drugs have resulted in unmet medical needs for effective novel treatments. Several biologics offer better safety and efficacy over small molecules. Thus, the development of new biologics is expected to address the unmet needs for safe and novel treatment of open-angle glaucoma. This, in turn, will boost the growth of the market during the forecast period. Continue Reading Technavio has announced its latest market research report titled Global Open-Angle Glaucoma Therapeutics Market 2022-2026 The open-angle glaucoma therapeutics market size is expected to grow by USD 2.58 billion from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 7.18% during the forecast period, according to Technavio. The promising pipeline and recent approvals are driving the open-angle glaucoma therapeutics market growth. However, factors such as advances in glaucoma surgeries may challenge the market growth. Get a comprehensive report summary that describes the market size and forecast along with research methodology. The FREE sample report is available in PDF format Open-Angle Glaucoma Therapeutics Market: Product Landscape By product, the market has been segmented into PGAs and non-PGAs. The PGAs segment will be the largest contributor to market growth during the forecast period. PGAs are the first-line treatment for open-angle glaucoma. Currently, Bimatoprost, latanoprost, and travoprost are the available PGAs in the market, which are approved for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Such factors will boost the market growth during the forecasted period. Open-Angle Glaucoma Therapeutics Market: Geographic Landscape By geography, the market has been segmented into North America, Europe, APAC, and Rest of World (ROW). North America is going to have lucrative growth during the forecast period. About 51% of the market's overall growth is expected to originate from the region. The US and Canada are the key countries in the open-angle glaucoma therapeutics market in North America. Open-Angle Glaucoma Therapeutics Market: Key Companies and their Offerings AbbVie Inc., Aerie Pharmaceuticals Inc, Alcon Inc., Bausch Health Co Inc, D.Western, Therapeutics Institute Inc, Hikma Pharmaceuticals Plc, Laboratories Sophia, Merck and Co. Inc., Nicox SA, Novartis AG, Ocuphire Pharma Inc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., PharmaMar SA, Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., among others, are the main players in the market. The key offerings of some of these vendors are listed below: AbbVie Inc. - The company offers open-angle glaucoma therapeutics such as Lumigan and Combigan. Aerie Pharmaceuticals Inc - The company offers open-angle glaucoma therapeutics, namely Rocklatan and Rhopressa. Alcon Inc. - The company offers open-angle glaucoma therapeutics, namely Travatan. Bausch Health Co Inc - The company offers open-angle glaucoma therapeutics, namely Vyzulta. Hikma Pharmaceuticals Plc - The company offers open-angle glaucoma therapeutics, namely Diazepam. This report provides a full list of key vendors, their strategies, and the latest developments. Request a FREE PDF Sample Now Open-Angle Glaucoma Therapeutics Market: What Our Reports Offer Market share assessments for the regional and country-level segments Strategic recommendations for the new entrants Covers market data for 2021, 2022, until 2026 Market trends (drivers, opportunities, threats, challenges, investment opportunities, and recommendations) Strategic recommendations in key business segments based on the market estimations Competitive landscaping mapping the key common trends Company profiling with detailed strategies, financials, and recent developments Supply chain trends mapping the latest technological advancements Related Reports Myopia and Presbyopia Treatment Market by Type and Geography - Forecast and Analysis 2022-2026: The myopia and presbyopia treatment market share is expected to increase by USD 7.22 billion from 2021 to 2026. Ophthalmology Therapeutics Market by Product and Geography - Forecast and Analysis 2021-2025: The ophthalmology therapeutics market size has the potential to grow by USD 12.34 billion during 2020-2025 Browse Health Care Market Reports Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Product 5.1 Market segments Exhibit 24: Chart on Product - Market share 2021-2026 (%) Exhibit 25: Data Table on Product - Market share 2021-2026 (%) 5.2 Comparison by Product Exhibit 26: Chart on Comparison by Product Exhibit 27: Data Table on Comparison by Product 5.3 PGAs - Market size and forecast 2021-2026 Exhibit 28: Chart on PGAs - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on PGAs - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on PGAs - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on PGAs - Year-over-year growth 2021-2026 (%) 5.4 Non-PGAs - Market size and forecast 2021-2026 Exhibit 32: Chart on Non-PGAs - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Non-PGAs - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Non-PGAs - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Non-PGAs - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Product Exhibit 36: Market opportunity by Product ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 APAC - Market size and forecast 2021-2026 Exhibit 50: Chart on APAC - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on APAC - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on APAC - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on APAC - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Canada - Market size and forecast 2021-2026 Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.9 Japan - Market size and forecast 2021-2026 Exhibit 66: Chart on Japan - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on Japan - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on Japan - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on Japan - Year-over-year growth 2021-2026 (%) 7.10 UK - Market size and forecast 2021-2026 Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.11 Germany - Market size and forecast 2021-2026 Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.12 Mexico - Market size and forecast 2021-2026 Exhibit 78: Chart on Mexico - Market size and forecast 2021-2026 ($ million) Exhibit 79: Data Table on Mexico - Market size and forecast 2021-2026 ($ million) Exhibit 80: Chart on Mexico - Year-over-year growth 2021-2026 (%) Exhibit 81: Data Table on Mexico - Year-over-year growth 2021-2026 (%) 7.13 Market opportunity by geography Exhibit 82: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 83: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 84: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 85: Overview on factors of disruption 9.4 Industry risks Exhibit 86: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 87: Vendors covered 10.2 Market positioning of vendors Exhibit 88: Matrix on vendor position and classification 10.3 AbbVie Inc. Exhibit 89: AbbVie Inc. - Overview Exhibit 90: AbbVie Inc. - Product / Service Exhibit 91: AbbVie Inc. - Key offerings 10.4 Aerie Pharmaceuticals Inc Exhibit 92: Aerie Pharmaceuticals Inc - Overview Exhibit 93: Aerie Pharmaceuticals Inc - Product / Service Exhibit 94: Aerie Pharmaceuticals Inc - Key offerings 10.5 Alcon Inc. Exhibit 95: Alcon Inc. - Overview Exhibit 96: Alcon Inc. - Business segments Exhibit 97: Alcon Inc. - Key offerings Exhibit 98: Alcon Inc. - Segment focus 10.6 Bausch Health Co Inc Exhibit 99: Bausch Health Co Inc - Overview Exhibit 100: Bausch Health Co Inc - Business segments Exhibit 101: Bausch Health Co Inc - Key news Exhibit 102: Bausch Health Co Inc - Key offerings Exhibit 103: Bausch Health Co Inc - Segment focus 10.7 Hikma Pharmaceuticals Plc Exhibit 104: Hikma Pharmaceuticals Plc - Overview Exhibit 105: Hikma Pharmaceuticals Plc - Business segments Exhibit 106: Hikma Pharmaceuticals Plc - Key offerings Exhibit 107: Hikma Pharmaceuticals Plc - Segment focus 10.8 Nicox SA Exhibit 108: Nicox SA - Overview Exhibit 109: Nicox SA - Product / Service Exhibit 110: Nicox SA - Key offerings 10.9 Novartis AG Exhibit 111: Novartis AG - Overview Exhibit 112: Novartis AG - Business segments Exhibit 113: Novartis AG - Key offerings Exhibit 114: Novartis AG - Segment focus 10.10 Otsuka Pharmaceutical Co. Ltd. Exhibit 115: Otsuka Pharmaceutical Co. Ltd. - Overview Exhibit 116: Otsuka Pharmaceutical Co. Ltd. - Product / Service Exhibit 117: Otsuka Pharmaceutical Co. Ltd. - Key offerings 10.11 Pfizer Inc. Exhibit 118: Pfizer Inc. - Overview Exhibit 119: Pfizer Inc. - Product / Service Exhibit 120: Pfizer Inc. - Key news Exhibit 121: Pfizer Inc. - Key offerings 10.12 Viatris Inc. Exhibit 122: Viatris Inc. - Overview Exhibit 123: Viatris Inc. - Business segments Exhibit 124: Viatris Inc. - Key offerings Exhibit 125: Viatris Inc. - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 126: Inclusions checklist Exhibit 127: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 128: Currency conversion rates for US$ 11.4 Research methodology Exhibit 129: Research methodology Exhibit 130: Validation techniques employed for market sizing Exhibit 131: Information sources 11.5 List of abbreviations Exhibit 132: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

小分子药物

100 项与 D. Western Therapeutics Institute, Inc. 相关的药物交易

登录后查看更多信息

100 项与 D. Western Therapeutics Institute, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床1期

临床2期

申请上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

DW-5LBT	神经痛更多	申请上市
H-1337 ( LRRK2 x PKA x PKD1 x PKN2 )	开角型青光眼1A 更多	临床2期
DW-1001	眼部疾病更多	临床1期
Cotosudil ( HSP90 x ROCK2 )	脉络膜新生血管更多	临床前
DWR-2206	大疱性角膜病变更多	临床前